CA Patent

CA2862320A1 — Method of treatment of nasopharyngeal cancer

Assigned to Millennium Pharmaceuticals Inc · Expires 2013-08-01 · 13y expired

What this patent protects

The present invention provides a method of treating nasopharyngeal cancer with a proteasome inhibitor of formula (7). The invention also provides a method of treating a patient with nasopharyngeal cancer based on elevated expression levels of NFkB, as measured by a H-score of the…

USPTO Abstract

The present invention provides a method of treating nasopharyngeal cancer with a proteasome inhibitor of formula (7). The invention also provides a method of treating a patient with nasopharyngeal cancer based on elevated expression levels of NFkB, as measured by a H-score of the patient's nasopharyngeal cancer tumor sample using a "NFkB p65 IHC assay. The invention also provides a method of determing whether to treat a patient with the compound of formula (/) based on the level of NFkB p65 in the patient's nasopharyngeal cancer tumor sample.

Drugs covered by this patent

Patent Metadata

Patent number
CA2862320A1
Jurisdiction
CA
Classification
Expires
2013-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Millennium Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.